Method of inhibiting pancreatic &bgr;-cell p135 O-glycosylation
    4.
    发明授权
    Method of inhibiting pancreatic &bgr;-cell p135 O-glycosylation 失效
    抑制胰腺β细胞p135 O-糖基化的方法

    公开(公告)号:US06589995B2

    公开(公告)日:2003-07-08

    申请号:US09813534

    申请日:2001-03-21

    CPC classification number: A61K31/655

    Abstract: The present invention demonstrates a method for inhibiting O-linked protein glycosylation in a tissue or cell, comprising the step of contacting said tissue or cell with (Z)-1-[N-(3-Ammoniopropyl)-N-(n-propyl)amino] diazen-ium-1,2-diolate or a derivative thereof. The present invention is also directed to a method of treating or inhibiting the onset of diabetes mellitis in an individual in need of such treatment, comprising the step of admininstering to said individual a pharmacological dose of a compound which inhibiting O-linked protein glycosylation in a tissue or cell of said individual. Further, the present invention provides a pharmaceutical composition, comprising (Z)-1-[N-(3-Ammoniopropyl)-N-(n-propyl)amino] diazen-ium-1,2-diolate and a pharmaceutically acceptable carrier or a derivative thereof.

    Abstract translation: 本发明揭示了一种抑制组织或细胞中O-连锁蛋白糖基化的方法,包括使所述组织或细胞与(Z)-1- [N-(3-氨基丙基)-N-(正丙基) )氨基]二氮烯-1,2-二醇酯或其衍生物。 本发明还涉及在需要这种治疗的个体中治疗或抑制糖尿病发病的方法,其包括以下步骤:向所述个体施用在一种或多种药物中抑制O-连接蛋白糖基化的化合物的药理学剂量 所述个体的组织或细胞。 此外,本发明提供了一种药物组合物,其包含(Z)-1- [N-(3-氨基丙基)-N-(正丙基)氨基]二氮烯-1,2-二醇酯和药学上可接受的载体或 其衍生物。

Patent Agency Ranking